About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Epilepsy Clinical Trials in New York | 155 Studies | Clareo Health

Clinical Trials EpilepsyNew York

Epilepsy Clinical Trials in New York

Find 155 clinical trials for epilepsy near New York, New York. Connect with research centers in your area.

All Epilepsy trials nationwide All trials in New York

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 41-60 of 155 trials

AVAILABLE< 1 mile

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

NCT04457687

The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.

Epilepsies, MyoclonicDrug Resistant Epilepsy

Birmingham, Alabama, United States • Los Angeles, California, United States • Aurora, Colorado, United States +19 more locations

COMPLETEDNA< 1 mile

Stereotactic Laser Ablation for Temporal Lobe Epilepsy (Slate)

NCT02844465

The study is designed to evaluate the safety and efficacy of the Visualase MRI-guided laser ablation system for mesial temporal epilepsy (MTLE).

Temporal Lobe Epilepsy

MedtronicNeuro167 participantsStarted Dec 2016

Newport Beach, California, United States • Palo Alto, California, United States • San Francisco, California, United States +20 more locations

Epilepsy Trials in Other Cities

Los Angeles Chicago Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

Active Not RecruitingNA< 1 mile

Memory Retrieval and Encoding Investigated by Neural Stimulation

NCT04286776

The purpose of this research is to understand biomarkers of human memory through correlational analyses and to use focal electrical stimulation as a causal manipulation to understand how biomarkers of memory relate to other brain states and behavioral measures.

Epilepsy Intractable

University of Pennsylvania800 participantsStarted Oct 2014

Aurora, Colorado, United States • Atlanta, Georgia, United States • Bethesda, Maryland, United States +8 more locations

TERMINATEDPhase 3< 1 mile

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

NCT04639310

To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).

EpilepsyEpilepsy in ChildrenEpilepsy; Seizure+5 more

Xenon Pharmaceuticals Inc.8 participantsStarted Mar 2021

Orange, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +17 more locations

TERMINATEDNA< 1 mile

Feasibility Study on LITT for Medical Refractory Epilepsy

NCT02820740

Multicenter, open-label, prospective designed study to characterize the performance of brain laser interstitial thermal therapy (LITT) ablation using the Monteris NeuroBlate System for the treatment of drug-refractory medial temporal lobe epilepsy in subjects who are candidates for LITT surgery.

Monteris Medical4 participantsStarted Apr 2017

Phoenix, Arizona, United States • New Haven, Connecticut, United States • Kansas City, Kansas, United States +2 more locations

TERMINATEDPhase 4< 1 mile

Perampanel Titration and Cognitive Effects

NCT04417907

The objective of this study is to determine whether there are any differences in the cognitive abilities and/or behavioral response of normal healthy volunteers across different titration rates of perampanel.

Kimford Jay Meador29 participantsStarted Oct 2021

Palo Alto, California, United States • Chicago, Illinois, United States • New York, New York, United States

COMPLETEDPhase 2< 1 mile

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

NCT03373383

The purpose of the study is to characterize the dose-response relationship with respect to efficacy of Padsevonil administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy.

Drug-resistant EpilepsyFocal-Onset Seizures

UCB Biopharma S.P.R.L.411 participantsStarted Feb 2018

Chandler, Arizona, United States • Little Rock, Arkansas, United States • La Jolla, California, United States +145 more locations

COMPLETEDNA< 1 mile

Presurgical Motor Mapping With Transcranial Magnetic Stimulation (TMS)

NCT02741193

The aim of the study is to examine the degree of concordance between presurgical neuronavigation guided TMS (nTMS) and direct cortical stimulation (DCS) in identifying hand motor cortex in adults undergoing epilepsy surgery. Navigated transcranial magnet stimulation (nTMS), MagStim RapidStim2 Magnetic stimulation will be delivered to hand primary motor cortex, with positive and negative functional sites determined through surface electromyography (EMG). The study will involve patients ages 12-60 years, with planned neurosurgery involving implantation of intracranial subdural electrodes including over the precentral gyrus. Navigated transcranial magnet stimulation (nTMS), MagStim RapidStim2 Magnetic stimulation will be delivered to hand primary motor cortex, with positive and negative functional sites determined through surface electromyography (EMG). The primary outcome measure will be spatial correlation between topographic maps of hand motor representation obtained through nTMS compared to direct, extra-operative cortical stimulation performed as part of routine clinical care. A secondary outcome measure will be safety and tolerability of TMS in the epilepsy patients.

NYU Langone Health2 participantsStarted Sep 2016

New York, New York, United States

COMPLETED< 1 mile

Rolandic Epilepsy Genomewide Association International Study

NCT03547050

We have discovered a small change in the genetic code which increases the risk of the brainwave abnormality that is found in rolandic epilepsy. We now wish to confirm this using a second much larger sample of patients. We will investigate the other genetic changes that cause people with the brainwave abnormality to develop seizures, as well as problems with speech, coordination, attention and learning.

Rolandic Epilepsy

King's College London210 participantsStarted Jun 2018

New York, New York, United States • Providence, Rhode Island, United States • Seattle, Washington, United States +10 more locations

COMPLETED< 1 mile

Human Epilepsy Project 2: Resistant Focal Seizures Study

NCT03531008

The HEP2 study is designed to better understand the challenges of living with focal seizures that do not respond to medication, by following 205 people with medication-resistant focal epilepsy over two years to measure changes in health status, healthcare costs, quality of life, and biomarkers of epilepsy severity and treatment response.

EpilepsyBrain DiseasesCentral Nervous System Diseases+2 more

Epilepsy Foundation of America157 participantsStarted May 2018

San Francisco, California, United States • New Haven, Connecticut, United States • Miami, Florida, United States +7 more locations

COMPLETED< 1 mile

Genetics of Rolandic Epilepsy

NCT00282854

The purpose of this study is to find the genes that cause Rolandic epilepsy and its related traits.

King's College London1,000 participantsStarted Jan 2005

New York, New York, United States

UNKNOWNPhase 2< 1 mile

Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy

NCT05063877

This is a double-blind, placebo controlled, randomized study of dose-ranging safety, tolerability, exploratory efficacy of adjunctive EQU-001 for seizures using the continuous reassessment method in patients diagnosed with epilepsy.

Equilibre Biopharmaceuticals B.V.43 participantsStarted Aug 2021

Boise, Idaho, United States • Bethesda, Maryland, United States • Hackensack, New Jersey, United States +7 more locations

COMPLETEDPhase 317 miles

A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome

NCT02682927

Study 1 and Study 3 are the prospective, merged analyses of 2 identical double-blind, placebo-controlled studies, ZX008-1501 and ZX008-1502, to assess the efficacy, safety, and pharmacokinetics of ZX008 when used as adjunctive therapy in pediatric and young adult subjects with Dravet syndrome. Study 1501 and Study 1502 were conducted in parallel; Study 1501 was conducted at approximately 30 study sites in North America; Study 1502 was conducted at approximately 30 study sites in Europe, Asia and Australia. Upon completion of the Baseline Period after initial Screening and Baseline charting of seizure frequency, subjects who qualified for the studies were randomized (1:1:1) in a double-blind manner to receive either 1 of 2 doses of ZX008 (0.2 mg/kg/day or 0.8 mg/kg/day; maximum dose: 30 mg/day) or placebo. Randomization was stratified by age group (\< 6 years, ≥6 to 18 years) to achieve balance across treatment arms, with the target of 25% of subjects in each age group. All subjects were titrated to their randomized dose over a 14-day Titration Period. Following titration, subjects continued treatment at their randomly assigned dose over a 12-week Maintenance Period. Subjects exiting the study underwent a 2-week taper, unless they enrolled in a follow-on study. Subjects were followed for post-study safety monitoring.

Dravet SyndromeSeizure Disorder

Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.262 participantsStarted Jan 2016

Phoenix, Arizona, United States • Tucson, Arizona, United States • San Diego, California, United States +52 more locations

COMPLETED70 miles

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326

Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved. A total of approximately 7000 children aged \<21 years who are receiving these drugs for standard of care will be enrolled and will be followed for up a maximum of 90 days. The goal of this study is to characterize the pharmacokinetics of understudied drugs for which specific dosing recommendations and safety data are lacking. The prescribing of drugs to children will not be part of this protocol. Taking advantage of procedures done as part of routine medical care (i.e. blood draws) this study will serve as a tool to better understand drug exposure in children receiving these drugs per standard of care. The data collected through this initiative will also provide valuable pharmacokinetic and dosing information of drugs in different pediatric age groups as well as special pediatric populations (i.e. obese).

AdenovirusAnesthesiaAnxiety+56 more

Daniel Benjamin3,520 participantsStarted Nov 2011

Anchorage, Alaska, United States • Little Rock, Arkansas, United States • La Jolla, California, United States +49 more locations

COMPLETED80 miles

Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

NCT03529045

Multicenter global post-market registry of subjects diagnosed with drug resistant epilepsy and treated with the VNS Therapy System.

EpilepsySeizuresDrug Resistant Epilepsy

LivaNova827 participantsStarted Feb 2018

Grand Junction, Colorado, United States • Washington D.C., District of Columbia, United States • Orlando, Florida, United States +59 more locations

COMPLETEDPhase 2152 miles

Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)

NCT03865732

A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone therapy compared to placebo for the treatment of seizures in female children and young adults with genetically confirmed PCDH19 gene mutation.

PCDH19-Related Epilepsy

Marinus Pharmaceuticals29 participantsStarted May 2019

Little Rock, Arkansas, United States • Los Angeles, California, United States • San Francisco, California, United States +9 more locations

COMPLETED155 miles

Prospective Research in Infants With Mild Encephalopathy

NCT01747863

A multicenter observational pilot study will be conducted to determine the natural history of infants with early diagnosis (≤ 6 hrs of age) of mild neonatal encephalopathy (NE) who are not qualified for therapeutic hypothermia. The intervention includes: neurologic examination by using modified Sarnat score at ≤ 6 hrs of age, 24 hrs and before discharge home, amplitude-integrated electroencephalography (aEEG) at 6 ± 3 hrs of age, brain MRI at before discharge home to 30 days of age and follow-up at 18-22 months of age. Primary outcome is the percentage of mild NE infants with evidence of brain injury defined by the presence of at least 1 abnormality of brain MRI, aEEG or neurologic examination in the neonatal period. Secondary outcome is the percentage of brain MRI, aEEG and neurological exam abnormalities, seizure, length of hospital stay, need of gavage feeds or gastrostomy at discharge home, death and long-term outcome.

Hypoxic-Ischemic EncephalopathyBrain InjuryNeonatal Seizure

McGill University Health Centre/Research Institute of the McGill University Health Centre63 participantsStarted Dec 2012

Detroit, Michigan, United States • Columbus, Ohio, United States • Providence, Rhode Island, United States +4 more locations

UNKNOWN190 miles

Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services

NCT06082999

Overall, this observational cohort study aims too: 1. Implement rapid trio WGS for all children presenting to our health systems with epilepsy onset under 12 months of age. 2. Utilize electronic healthcare records and research databases to unite phenotypic and genomic data and to create a "virtual" registry across all institutions that will promote ongoing discovery. 3. Assess the impact of early genetic diagnosis on epilepsy, developmental, and health economic outcomes through formal longitudinal assessments of all children enrolled.

Great Ormond Street Hospital for Children NHS Foundation Trust300 participantsStarted Sep 2021

Boston, Massachusetts, United States • Parkville, Victoria, Australia • Toronto, Ontario, Canada +1 more locations

WITHDRAWNNA332 miles

Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery

NCT04344626

Refractory epilepsy, meaning epilepsy that no longer responds to medication, is a common neurosurgical indication in children. In such cases, surgery is the treatment of choice. Complete resection of affected brain tissue is associated with highest probability of seizure freedom. However, epileptogenic brain tissue is visually identical to normal brain tissue, complicating complete resection. Modern investigative methods are of limited use. An important subjective assessment during surgery is that affected brain tissue feels stiffer, however there is presently no way to determine this without committing to resecting the affected area. It is hypothesized that intra-operative use of a tonometer (Diaton) will identify abnormal brain tissue stiffness in affected brain relative to normal brain. This will help identify stiffer brain regions without having to resect them. The objective is to determine if intra-operative use of a tonometer to measure brain tissue stiffness will offer additional precision in identifying epileptogenic lesions. In participants with refractory epilepsy, various locations on the cerebral cortex will be identified using standard pre-operative investigations like magnetic resonance imagin (MRI) and positron emission tomography (PET). These are areas of presumed normal and abnormal brain where the tonometer will be used during surgery to measure brain tissue stiffness. Brain tissue stiffness measurements will then be compared with results of routine pre-operative and intra-operative tests. Such comparisons will help determine if and to what extent intra-operative brain tissue stiffness measurements correlate with other tests and help identify epileptogenic brain tissue. 24 participants have already undergone intra-operative brain tonometry. Results in these participants are encouraging: abnormally high brain tissue stiffness measurements have consistently been identified and significantly associated with abnormal brain tissue. If the tonometer adequately identifies epileptogenic brain tissue through brain tissue stiffness measurements, it is possible that resection of identified tissue could lead to better post-operative outcomes, lowering seizure recurrences and neurological deficits.

EpilepsyFocal Cortical DysplasiaTuberous Sclerosis+7 more

University of California, Los AngelesStarted Jul 2018

Los Angeles, California, United States • Montreal, Quebec, Canada

TERMINATEDPhase 3464 miles

Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures

NCT05288283

The primary aim of Part A of the study to assess the efficacy and tolerability of GWP42003-P compared to placebo as an adjunctive treatment for children with Epilepsy with myoclonic-atonic seizures (EMAS) -associated seizures. Part B of this study will be conducted to evaluate the long-term safety and tolerability of GWP42003-P in participants with EMAS.

Seizures Associated With EMAS

Jazz Pharmaceuticals3 participantsStarted Oct 2022

Birmingham, Alabama, United States • Sacramento, California, United States • Atlanta, Georgia, United States +11 more locations

PreviousPage 3 of 8Next

Other Conditions in New York

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia